key: cord-0860587-c5zcjhp2
authors: Innao, Vanessa; Urso, Salvatore; Insalaco, Monica; Borraccino, Albino; Consoli, Ugo
title: Immune Thrombotic Thrombocytopenic Purpura following Pfizer-BioNTech anti-COVID-19 vaccination in a patient healed from lymphoma after allogeneic hematopoietic stem cell transplantation
date: 2022-01-04
journal: Thromb Res
DOI: 10.1016/j.thromres.2021.12.029
sha: 733433a6f017698337528d16f1b7381060174f4b
doc_id: 860587
cord_uid: c5zcjhp2

nan

Dear Editor, over the last year, reports of adverse events from SARS-CoV2 vaccines are proliferated, so we want to help improve knowledge on this subject by describing a case of de novo immune Thrombotic Thrombocytopenic Purpura (TTP) after Pfizer anti-SARS-CoV2 vaccination in a patient who achieved a long full remission of gray zone lymphoma after allogeneic hematopoietic stem cell transplantation.

Several cases of TTP are generally idiopathic, but different inducing agents have been described, such as malignancies, viral or bacterial infections, pregnancy, autoimmune disorders and drugs. H1N1 influenza, pneumococcal or rabies vaccination has led to the development of several immune-mediated pathological conditions, and many cases of atypical thrombosis such as TTP [1] [2] [3] . AstraZeneca-Oxford COVID-19 vaccine has been correlated with vaccine-induced thrombotic events, such as atypical thrombosis, the new clinical picture known as vaccine-immune thrombotic thrombocytopenia (VITT) [4] and rare cases of immune TTP [5] .

Anti-SARS-CoV2 m-RNA vaccines, such as Pfizer and Moderna, may also lead to immune mediated thrombocytopenia [6] , but no increase of immune-mediate thrombosis following COVID-19 vaccination has been reported in literature [7] .

Our case describes a 33-year-old white female who was admitted to Emergency Room of our hospital for marked asthenia, drowsiness, headache, nausea with abdominal pain, and lower extremity purpura, 9 days after I dose of Pfizer-BioNTech COVID19 vaccine. Physical examination revealed a Glasgow Coma Scale (GCS) score 4. Laboratory tests revealed severe anemia (hemoglobin 68 g/L) with reticulocytosis and critical thrombocytopenia (platelets 12 x 10 9 /L), elevated lactate dehydrogenase (1.280 U/L) and total bilirubin (2.3 mg/dl), and decreased haptoglobin level (<0.06 g/L), suggesting a hemolysis. Direct and indirect Coombs test was negative, standard coagulation tests were normal, creatinine was slightly altered (1.38 mg/dl), and negative was the search for antiphospholipid antibodies. Peripheral blood smear (PBS) test showed the presence of 3% schistocytes, which indicated iTTP diagnosis. Baseline analysis of enzymatic J o u r n a l P r e -p r o o f activity of ADAMTS13 with rapid test HemosIL AcuStar was performed, revealing reduced activity (8%), but the detection of antibodies against the metalloprotease was not valuable, due to defects in the sample. Brain Computed Tomography scan documented the presence of hyperattenuating micro-lesions, while microbiological tests on blood and urine showed negative results.

The patient's basal laboratory results are shown in Table 1 . The immunocompromised status of our patient, due to previous chemotherapy and autologous and allogeneic stem cell transplantations, could be assumed to be a contributing factor in triggering immune TTP. However, she has not shown more susceptibility to infections over the years, following allogeneic transplantation, and we have not sufficient data to claim that the dysregulation of her immune system may have encouraged the development of TTP.

With increasing anti Covid-19 vaccine distribution, it is essential for emergency clinicians to be aware of the evaluation and management of some life-threatening autoimmune condition, such as immune TTP or VITT, similar clinical conditions but with different pathogenesis, that deserve different ready-to-use therapeutic approaches. 

Very severe thrombotic thrombocytopenic purpura (TTP) after H1N1 vaccination

Acute thrombotic thrombocytopenic purpura after pneumococcal vaccination

Rabies vaccine-associated thrombotic thrombocytopenic purpura

Thrombosis and Thrombocytopenia after

Acquired thrombotic thrombocytopenic purpura with possible association with AstraZeneca-Oxford COVID-19 vaccine

Thrombocytopenia following Pfizer and Moderna SARS-CoV-2 vaccination

SARS-CoV-2 Vaccine and Thrombosis: An Expert Consensus of Vaccine-Induced Immune Thrombotic Thrombocytopenia

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination

Insights in ChAdOx1 nCov-19 Vaccine-induced Immune Thrombotic Thrombocytopenia (VITT)

Immune-mediated thrombotic thrombocitopenic purpura following Pfizer-BioNTech COVID-19 vaccine

Anti-ADAMTS13 IgG antibodies* (U/ml) 5 n.v

Direct and Indirect Coombs tests Negative Negative Blood and urine microbiological tests Negative Negative Abbreviations: PBS: Peripheral blood smear; RBD: receptor binding domain; Ab-PF4: anti-platelet factor 4. * Data acquired at the second determination, after 3 days of PEX + Caplacizumab treatment